5 min read
Blog: Considerations for Abuse-Deterrent Category One Syringeability Studies
The use of opioid medications for pain management continues to increase, generating an inevitable association with abuse and addiction. Government...
1 min read
Alcami : Nov 16, 2017 8:00:00 AM
As of July 2017, America’s opioid crisis has been declared a state of emergency. In order to help combat prescription opioid drug misuse and abuse, pharmaceutical drug companies are developing and commercializing drug products that have abuse- deterrent features. The FDA issued guidance in April 2015 for new drug applications (NDAs), and suggested guidance in March 2016 for generic abbreviated new drug applications (ANDAs) to aid in the formal evaluation of the abuse-deterrent nature of drug products. A crucial test for drug products that are abused intravenously are syringeability studies. Because most syringeability studies are performed exclusively in-vitro due to the hazardous nature of abuse-deterrent formulation excipients, accurate experimental design is crucial and carefully reviewed by the FDA.
This webinar will:
5 min read
The use of opioid medications for pain management continues to increase, generating an inevitable association with abuse and addiction. Government...
3 min read
In 2011, the White House published “Epidemic: Responding to America's Prescription Drug Abuse Crisis,” which outlined a comprehensive strategy for...
7 min read
Increasing prevalence of drug misuse and abuse is driving a heightened and more stringent approach to abuse-deterrent formulations. Possibly the most...